Abstract
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease. We performed a comprehensive analysis to construct the correlation of m6A and immune in HCM. Two HCM datasets (GSE141910 and GSE160997) and m6A-related regulators were obtained from GEO and published articles, respectively. Differentially expressed m6A-related regulators were obtained. Random forest model and nomogram were conducted to assess the risk of HCM, and finally, the m6A subtype was constructed. Functional enrichment analysis was conducted. Protein-protein interaction network of differentially expressed genes between m6A subtypes was performed. Furthermore, we constructed the Hubgene-chemical network, Hubgene-microRNA network, and Hubgene-transcription factor network of the top 10 hubgenes. Additionally, the immune subtype and hubgene subtype were constructed. PCR was performed to validate the m6A-related regulators. We obtained 20 m6A-related regulators in HCM. Among them, 8 m6A-related regulators differentially expressed (YTHDC1, HNRNPC, and FMR1 were up-regulated while YTHDC2, FTO, WTAP, IGF2BP2, and IGF2BP3 were down-regulated). FTO, FMR1, IGF2BP3, YTHDC1, and IGF2BP2 were the top 5 important m6A-related regulators and were used to conduct the nomogram. We obtained 329 differentially expressed genes in m6A subtype and these genes enriched HCM-related processes and pathways. Furthermore, we constructed the Hubgene-chemical network, Hubgene-microRNA network, and Hubgene-transcription factor network of the top 10 hubgenes (NFKBIA, NFKB1, PSMA3, PSMC4, PSMA2, PSMA4, PSMD7, PSMD10, PSMD8, and PSMA6). And then we constructed an immune subtype based on the immune cell infiltration levels and hubgene subtype based on the expression of the top 10 hubgenes. Finally, we verified the main results through experiments. In conclusion, we built a nomogram and identified 8 m6A-related regulators and 10 hubgenes, which were prominently associated with HCM. We found that m6A and the immune system may play a crucial role in the HCM. Accordingly, those genes and pathways might become therapeutic targets with clinical usefulness in the future.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: GSE141910 and GSE160997
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
